Search research articles
Contact Us
Filters
Showing results (11-20 of 56) with videos related to
Page
of 6
Sort By:
Journal of Child and Adolescent Psychopharmacology
|
June 14, 2003
Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder
Jennifer W Witcher, Amanda Long, Brian Smith, et al.
Journal of Clinical Pharmacology
|
November 5, 2002
Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics
Donna J Belle, C Steven Ernest, John-Michael Sauer, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
November 6, 2016
Net Reclassification Index and Integrated Discrimination Index Are Not Appropriate for Testing Whether a Biomarker Improves Predictive Performance
Peter M Burch, Warren E Glaab, Daniel J Holder, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
December 18, 2002
Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism
John-Michael Sauer, G Douglas Ponsler, Edward L Mattiuz, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
November 6, 2024
Serum glutamate dehydrogenase activity enables sensitive and specific diagnosis of hepatocellular injury in humans
Jiri Aubrecht, David Potter, John Michael Sauer, et al.
Journal of Biomolecular Screening
|
April 5, 2012
Quantifying amyloid beta (Aβ)-mediated changes in neuronal morphology in primary cultures: implications for phenotypic screening
Lan Nguyen, Sarah Wright, Mike Lee, et al.
Biomarkers in Medicine
|
May 26, 2021
Perspectives on statistical strategies for the regulatory biomarker qualification process
Suzanne B Hendrix, Robin Mogg, Sue Jane Wang, et al.
Bioanalysis
|
August 12, 2025
Special consideration: commentary on the 2025 FDA Bioanalytical Method Validation for Biomarkers
Karen J Quadrini, Jiri Aubrecht, Nicholas M P King, et al.
Plos One
|
May 15, 2020
Serum glutamate dehydrogenase activity enables early detection of liver injury in subjects with underlying muscle impairments
Shelli Schomaker, David Potter, Roscoe Warner, et al.
Journal of Pharmaceutical Sciences
|
January 4, 2012
A formulation strategy for gamma secretase inhibitor ELND006, a BCS class II compound: development of a nanosuspension formulation with improved oral bioavailability and reduced food effects in dogs
Kevin Quinn, Rampurna Prasad Gullapalli, Elaine Merisko-Liversidge, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 56) with videos related to
Sort By:
Page
of 6
Journal of Child and Adolescent Psychopharmacology
|
June 14, 2003
Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder
Jennifer W Witcher, Amanda Long, Brian Smith, et al.
Journal of Clinical Pharmacology
|
November 5, 2002
Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics
Donna J Belle, C Steven Ernest, John-Michael Sauer, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
November 6, 2016
Net Reclassification Index and Integrated Discrimination Index Are Not Appropriate for Testing Whether a Biomarker Improves Predictive Performance
Peter M Burch, Warren E Glaab, Daniel J Holder, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
December 18, 2002
Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism
John-Michael Sauer, G Douglas Ponsler, Edward L Mattiuz, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
November 6, 2024
Serum glutamate dehydrogenase activity enables sensitive and specific diagnosis of hepatocellular injury in humans
Jiri Aubrecht, David Potter, John Michael Sauer, et al.
Journal of Biomolecular Screening
|
April 5, 2012
Quantifying amyloid beta (Aβ)-mediated changes in neuronal morphology in primary cultures: implications for phenotypic screening
Lan Nguyen, Sarah Wright, Mike Lee, et al.
Biomarkers in Medicine
|
May 26, 2021
Perspectives on statistical strategies for the regulatory biomarker qualification process
Suzanne B Hendrix, Robin Mogg, Sue Jane Wang, et al.
Bioanalysis
|
August 12, 2025
Special consideration: commentary on the 2025 FDA Bioanalytical Method Validation for Biomarkers
Karen J Quadrini, Jiri Aubrecht, Nicholas M P King, et al.
Plos One
|
May 15, 2020
Serum glutamate dehydrogenase activity enables early detection of liver injury in subjects with underlying muscle impairments
Shelli Schomaker, David Potter, Roscoe Warner, et al.
Journal of Pharmaceutical Sciences
|
January 4, 2012
A formulation strategy for gamma secretase inhibitor ELND006, a BCS class II compound: development of a nanosuspension formulation with improved oral bioavailability and reduced food effects in dogs
Kevin Quinn, Rampurna Prasad Gullapalli, Elaine Merisko-Liversidge, et al.
Page
of 6